William Sellers
Has grant
Professor of Medicine
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
Surfaceome Target Discovery for Next-Generation Therapies in Biliary Tract Cancers
Open Date: 2026-02-01
Close Date: 2028-01-31
Articles (9)
Year:
2026
A high therapeutic index, defined as potent inhibition of oncogenic signaling in tumor cells with minimal effects on normal cells, is critical for effective cancer therapies. Recent advances have introduced diverse RAS-targeting inhibitors, including mutant-specific inhibitors such as KRAS G12C and KRAS G12D, as well as paralog- and state-selective inhibitors. Non–mutant-specific RAS inhibition can be achieved by: (i) guanine nucleotide exchange–OFF inhibitors that indirectly inactivate RAS by targeting SHP2 or SOS1, (ii) KRAS-OFF inhibitors that spare NRAS and HRAS, and (iii) active-state RAS(ON) inhibitors that directly block binding of effector RAF. However, the signaling inhibition index (SII)—the differential suppression of oncogenic signaling between RAS-mutant and normal cells—remains poorly defined for these approaches. We evaluated the SII for state- and paralog-selective RAS inhibitors across diverse RAS-mutant and RAS–wild-type models. Guanine nucleotide exchange–OFF inhibitors exhibited neutral or negative values, with reduced MAPK suppression in KRAS G12X cells compared with wild-type cells. KRAS G13D models, especially with NF1 loss, showed low sensitivity. SHP2 plus MEK inhibition resulted in low selectivity, and RAS Q61X models were resistant due to MEK inhibitor–induced NRAS reactivation and altered SHP2 conformations. KRAS-OFF inhibitors demonstrated higher selectivity, whereas active- state RAS(ON) inhibitors showed broader activity but narrow selectivity. Sensitivity to mutant-specific inhibitors largely overlapped with sensitivity to state-selective agents, suggesting that most RAS-mutant tumors will respond poorly to any currently available RAS inhibitor. Implications: Determining the SII can inform the design and clinical application of RAS-targeted therapies to improve tumor selectivity and therapeutic outcomes.
Year:
2026
Year:
2025
Cyclin-dependent kinase inhibitor 2A ( CDKN2A ) / methylthioadenosine phosphorylase ( MTAP ) codeletion occurs frequently in non–small cell lung cancer and other solid tumors, including glioblastoma and pancreatic ductal adenocarcinoma. Lung cancer remains the leading cause of cancer-related mortality, and fewer than 15% of patients with glioblastoma or pancreatic cancer survive 5 years, underscoring the need for more effective therapies. Protein arginine methyltransferase 5 (PRMT5) is a synthetic-lethal dependency in MTAP -null tumors and an attractive therapeutic target for CDKN2A/MTAP -deleted cancers. A new revolutionary class of inhibitors, referred to as methylthioadenosine (MTA)-cooperative PRMT5 inhibitors (PRMT5i), has shown promising results in ongoing early-phase clinical trials. Nonetheless, effective cancer treatment typically requires therapeutic combinations to improve response rates and defeat emergent resistant clones. Thus, we sought to determine whether perturbation of other pathways could improve the efficacy of MTA-cooperative PRMT5is (MTAC-PRMT5i). Using a paralog and single gene targeting CRISPR library, we screened MTAP -deleted cancers in the presence or absence of MTAC-PRMT5is. Loss of several genes sensitized cells to PRMT5 inhibition, including members of the MAPK pathway. Chemical inhibition of MAPK pathway members using KRAS, MEK, ERK, and RAF inhibitors synergized with PRMT5 inhibition to kill CDKN2A/MTAP -null, RAS-active tumors. Furthermore, MTAC-PRMT5is combined with either KRAS or RAF inhibitors led to complete responses in vivo , emphasizing the potential benefit for patients. Lastly, cell lines resistant to KRAS inhibition were not resistant to MTAC-PRMT5is and vice versa, suggesting noncross-reactive mechanisms of resistance. Overall, this study identifies therapeutic combinations with MTAC-PRMT5is that may offer significant benefits to patients. Significance: Combining PRMT5 and MAPK pathway inhibitors leads to complete, durable responses in lung cancer models, providing an effective therapeutic strategy for the 4-5% of cancer patients harboring CDKN2A/MTAP deletion and MAPK alterations. See related article by Drizyte-Miller et al., p. 3540
Year:
2025
Figure S10. Colony formation assays of three cell lines harboring CDKN2A/MTAP co-deletions and KRAS G12C mutations treated with KRAS G12C inhibitor adagrasib, PRMT5 inhibitor MRTX1719, or the combination across all drug concentrations.
Year:
2025
Biliary tract cancers (BTC) are aggressive malignancies encompassing intrahepatic and extrahepatic cholangiocarcinoma, gallbladder carcinoma, and ampullary carcinoma. Here, we report integrative analysis of 63 BTC cell lines via multi-omics and genome-scale CRISPR screens. We identify widespread EGFR dependency in BTC, alongside dependencies selective to anatomic subtypes. Additionally, we delineate strategies to overcome therapeutic resistance, with combined EGFR inhibition potentiating targeting of KRAS -mutant and FGFR2 fusion–driven models and SHP2 inhibition effective in the latter context. Clustering RNA/protein expression and dependencies data revealed functional relationships transcending single-gene alterations, with biliary, squamous, or dual biliary/hepatocyte lineage signatures stratifying BTC models. These subtypes exhibit distinct dependency profiles—including cell fate transcription factors GRHL2 , TP63 , and HNF1B , respectively—and demonstrate prognostic significance in patient samples. Potential subtype-specific targetable vulnerabilities include integrinα3 and the detoxification enzyme UXS1 . This cell line atlas reveals therapeutic targets in molecularly defined BTCs, unveils disease subtypes, and provides a resource for therapeutic development. Significance: This integrative analysis of BTC cell lines defines the landscape of vulnerabilities across BTCs, stratifying distinct subtypes, and provides a key resource for studying disease heterogeneity. The findings highlight strategies for targeting BTCs with specific genomic alterations, as well as broader approaches based on shared molecular programs and essential pathways.
Year:
2025
Inactivation of the VHL gene stabilizes HIF2α, which drives clear-cell renal cell carcinoma (ccRCC). The HIF2α inhibitor belzutifan is approved for ccRCC treatment, but de novo and acquired resistance are common. HIF2α, bound to ARNT, transcriptionally activates many genes. We performed CRISPR-mediated gene activation screens in HIF2α-dependent ccRCC lines treated with a belzutifan analog to identify HIF2α-responsive genes that confer cell-autonomous belzutifan resistance when not downregulated. Sustaining the expression of the HIF2α target gene CCND1 , encoding cyclin D1, promoted HIF2α independence/belzutifan resistance. This activity requires CDK4/6 activation by cyclin D1 but is not solely due to phosphorylation of the canonical cyclin D1 target, pRB. Indeed, ccRCC lines lacking all three pRB family members remained at least partially HIF2α-dependent. In this context, however, a kinase-defective cyclin D1 variant partially overrode belzutifan’s antiproliferative effects, suggesting that ccRCC promotion by cyclin D1 requires the phosphorylation of pRB paralogs and one or more kinase-independent cyclin D1 activities. Significance: We discovered that cyclin D1 is the key target of HIF2 driving the cell-autonomous proliferation of VHL -mutant kidney cancers and that cyclin D1 has targets beyond pRB in this setting. These findings have implications for treating kidney cancer with HIF2 inhibitors, alone or in combination with CDK4/6 inhibitors.
Year:
2025
Year:
2023
Year:
2023
Collaborators (18)
Paloma Cejas
Head of Innovation/Director
Dana-Farber Cancer Institute
Christos Adamopoulos
Assistant Professor
National and Kapodistrian University of Athens
Michael Lawrence
Assistant Professor
Broad Institute
Cristina Ferrone
Chair
Cedars-Sinai Medical Center
Poulikos Poulikakos
Professor
Icahn School of Medicine at Mount Sinai
William Kaelin
Sidney Farber Professor of Medicine
Dana-Farber Cancer Institute
Evripidis Gavathiotis
Professor
Albert Einstein College of Medicine
Stuart Aaronson
Professor and Founding Chair
Icahn School of Medicine at Mount Sinai
Kathleen Mulvaney
Assistant Professor
Virginia Tech
Srivatsan Raghavan
Assistant Professor
Dana-Farber Cancer Institute
WENYU YU
Harvard University
Meng-Ju Wu
Assistant Professor
University of Massachusetts Chan Medical School
Karen Adelman
Professor
Harvard Medical School
Gad Getz
Broad Institute
Matthew Hall
National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850
Nikola Knoll
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cyril Benes
Principal Investigator, Assistant in Genetics
Massachusetts General Hospital
Shaomeng Wang
Professor
University of Michigan
Make your next move.
Prepare your application
Review drafts before you send them.